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Abstract
Background: The efficacy and safety of intra-venous (i.v.) sodium benzoate for treating acute episodes of
hyperammonemia in urea cycle enzyme disorders (UCD) is well known. However, published data do not provide
a clear picture of the benefits and risks of this drug. We report a retrospective multicentre study on the use of i.v.
sodium benzoate in patients treated for UCD between 2000 and 2010 in the 6 French reference centres for
metabolic diseases.
Results: Sixty-one patients with UCDs - 22 ornithine transcarbamylase (20 confirmed, 2 suspected), 18 arginino-succinate
synthetase, 15 carbamoyl phosphate synthetase, 3 arginosuccinate lyase, 1 arginase deficiency, 1 N-acetylglutamate
synthetase, 1 HHH syndrome - required i.v. sodium benzoate over the course of 95 acute episodes (NH3 >
100 μmol/L or high-risk situations, i.e., gastroenteritis, surgery). Forty out of 61 patients experienced only one
episode of decompensation (neonatal coma, 68.6 %). The most frequent cause of late decompensation was
infection (55.5 %). A loading dose of i.v. sodium benzoate (median 250 mg/kg over 2 h) was administered for
41/95 acute episodes. The median maintenance dose was 246.1 mg/kg/day, administered via peripheral venous
infusion in all cases except one via a central line. The total median duration of i.v. sodium benzoate treatment
per episode was 2 days (0–13 days). The median durations of hospitalization in intensive care and metabolic
units were 4 days (0–17 days) and 10 days (0–70 days), respectively. Eight patients died during the neonatal
coma (n = 6) or surgery (n = 2). The median plasma ammonium level before treatment was 245.5 μmol/L (20.0–2274.
0 μmol/L); it decreased to 40.0 μmol/L in patients who were alive (13.0–181.0 μmol/L) at the end of treatment with i.v.
sodium benzoate. A decrease in ammonium level to≤ 100 μmol/L was obtained in 92.8 % of episodes (64/69 of the
episodes recorded for the 53 surviving patients). Five patients required another treatment for hyperammonemia
(sodium phenylacetate + sodium benzoate, haemofiltration). Eighteen side effects were reported related to the i.v.
infusion (local diffusion, oedema).
Conclusion: This 10-year retrospective study shows that i.v. sodium benzoate associated with an emergency regimen
is an effective and safe treatment for acute episodes of UCD.
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Background
The urea cycle is the single metabolic pathway that elim-
inates circulating ammonia, which is the nitrogen waste
product from protein catabolism and a potent neuro-
toxin. It involves a series of biochemical steps in which
nitrogen is removed from the blood and converted to
urea, which is non-toxic and excreted in the urine. Urea
cycle disorders (UCD) is a group of congenital disorders
caused by enzyme or transporter deficiencies that impair
the conversion of ammonia to urea. In UCDs, nitrogen
removal is blocked, and nitrogen accumulates in the
form of ammonia and other nitrogenous precursors of
urea, causing acute episodes of hyperammonemia. The
overall incidence of UCDs caused by enzyme deficiencies
is approximately 1:8000 [1, 2] or newly 1:35,000 new-
borns [3]. UCDs include ornithine transcarbamylase de-
ficiency (OTCD), the most common form; carbamoyl
phosphate synthetase deficiency (CPSD); arginino-
succinate synthetase deficiency (ASSD, citrullinemia type
I); arginosuccinate lyase deficiency (ASLD, arginino-
succinic aciduria); and more rarely, arginase deficiency
(ARGD) and N-acetylglutamate synthetase deficiency
(NAGSD). Hyperammonemia is also found in the
hyperornithinemia-hyperammonemia-homocitrullinuria
(HHH) syndrome caused by a mutation in the
SLC25A15 gene, which encodes the mitochondrial orni-
thine and citrulline transporter [4], and in lysinuric
protein intolerance (LPI) caused by inherited recessive
mutations in the SLC7A7 gene, which encodes for the
cationic amino-acids transporter subunit y + LAT1 lo-
cated on the basolateral plasma membrane of epithelial
cells and macrophages. Hyperammonemia can also be
associated with other inherited metabolic diseases
such as organic acidurias, mitochondrial fatty acid
oxidation defects and Carbonic anhydrase VA (CAVA)
deficiency, a new disease regulating carbamoyl phos-
phate synthetase 1, and with liver failure and certain
cases of iatrogenic intoxication, e.g., those caused by
sodium valproate [5].
If untreated, UCDs can cause increased levels of am-
monia in the bloodstream (a normal level of plasma am-
monium is < 100 μmol/L in neonates and < 50 μmol/L in
children and adults), resulting in vomiting, lethargy, sei-
zures, brain damage, coma and eventually, death. The
first episode of hyperammoniemia may occur at any age,
depending on the severity of the UC blockade. Neonatal
coma is the most common presentation, with a risk of
decompensation at any time throughout the lifespan,
despite adequate medical and dietary treatment. Despite
medical progress, UCDs remain at high risks of acute
decompensation with neurological sequelae and vital risk
[6], underlining the necessity of early diagnosis [7] and
intensive consensual protocols to optimise neonatal but
also long-term prognosis [2, 8–10].
The current treatment of UCD consists of a low-
protein diet associated with medications that provide
alternative pathways for the removal of nitrogenous
precursors of urea or ammonia from the bloodstream
[11]. Depending on the enzyme deficiency, these treat-
ments must be combined with daily L-arginine and/or
citrulline supplementation [12].
In cases of acute decompensation, and particularly in
emergency situations caused by infection, the major com-
plication of hyperammonemia is cerebral oedema [2, 13].
First-line emergency treatment depends on the clinical
status and whether the oral route is available for drug ad-
ministration. Treatment aims to normalize the plasma
ammonium level and restore the nitrogen balance (to en-
sure that input = loss), stop protein intake, administrate
emergency regimen with high lipid and carbohydrate in-
take, re-establish the excretion of excess nitrogen via the
administration of ammonium ion scavengers (orally or via
i.v.), and provide appropriate symptomatic management
(rehydration, correction of electrolyte imbalance). If ne-
cessary, extracorporeal toxin removal procedures should
be considered [14] (see below). After recovery and for the
long term, a low-protein diet and oral ammonium ion
scavengers should be prescribed.
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Two active substances have been identified as good
candidates to promote the removal of nitrogenous resi-
dues (and mainly ammonium ions) from the blood by
acting as an ammonium ion trap [15]: i) Sodium benzo-
ate conjugates with glycine to form hippurate, which is
eliminated by the kidneys (one mole of sodium benzoate
eliminates one mole of ammonia); ii) Sodium phenylace-
tate conjugates with glutamine to form phenylacetylglu-
tamine, which is eliminated by the kidneys (one mole of
sodium phenylacetate eliminates 2 moles of ammonia)
[16]. Sodium or glycerol (not yet marketed in France)
phenylbutyrate (per os), precursors of phenylacetate, also
eliminates 2 moles of ammonia per mole.
For the daily treatment and prevention of hyperammo-
nemia, sodium benzoate per os can be used with or
without sodium or glycerol phenylbutyrate.
In cases of acute hyperammonemia [4, 17], emergency
treatment in France consists of i) Sodium benzoate at a
loading dose by i.v. route [18]. This treatment, ‘sodium
benzoate AP-HP 1 g/10 mL solution for infusion’, is
available as a hospital preparation. It is produced by the
Pharmaceutical Establishment of the Paris Hospitals (As-
sistance Publique Hopitaux de Paris). Sodium phenylace-
tate can be combined with sodium benzoate (an equimolar
mixture of both products). The combination of these two
active substances is available in France on a named-patient
prescription basis (ATU) [19]. It must be administered via
a central venous catheter, which carries an increased risk
of complications (infection, thrombosis) and the need for
anaesthesia [20]. In cases of severe hyperammonemia
(>400 μmol/L), extracorporeal toxin removal procedures
[21] should be considered.
Despite the availability in France of the above-
mentioned ammonium scavengers and a relatively con-
sensual protocol for the treatment of acute episodes of
hyperammonemia [22], there are no data specifically
evaluating the efficacy of sodium benzoate for the treat-
ment of hyperammonemia. The aim of this study was to
evaluate the risk/benefit of providing i.v. sodium benzo-
ate treatment at the onset of the acute hyperammonemic
episodes and during the follow-up of UCD. We retro-
spectively studied patient files from all of the French ref-
erence centres specializing in the treatment of metabolic
diseases where this drug is the reference treatment for
acute episodes of hyperammoniemia.
Methods
Design
This was a retrospective multicentre study of the use of
i.v. sodium benzoate in UCD patients hospitalized for an
acute episode of decompensation with hyperammonemia
at a French Reference Centre of Metabolic Diseases
(Filière Maladies Métaboliques) between 2000 and 2010.
Because this was a retrospective cohort study, no control
group was deemed necessary. All hyperammonemia pa-
tients were treated with at least one dose of i.v. sodium
benzoate.
The primary objective of this study was to describe the
use of i.v. sodium benzoate for acute episodes of hyper-
ammonemia in UCD patients, focusing on the justifica-
tion of this treatment decision and the dosing schedule
(rate of infusion, duration of infusion, total dose of i.v.
sodium benzoate administered).
The secondary objective of this study was to describe
the efficacy and safety of i.v. sodium benzoate for treat-
ing acute episodes of hyperammoniemia, especially in
terms of the time course of ammonemia at admission,
during hospitalization and at the end of the episode, and
during the 24 h prior to discharge from hospital [16].
Patients and treatments
The six reference centres enrolled in this retrospective
study—Necker-Enfants Malades (AP-HP, Paris), Robert-
Debré (AP-HP, Paris), Hospices Civils de Lyon (HCL),
Jeanne-de-Flandre (Lille), La Timone (AP-HM, Marseille),
and Brabois (Nancy) - were asked to retrieve the medical
records of all patients with UCD who had been hospital-
ized between January 2000 and December 2010 in their
centers, with a diagnosis of hyperammonemia (>100 μmol/
L) or to minimize the likely risk of hyperammonemia and
for whom emergency treatment with i.v. sodium benzoate
was initiated.
Long-term treatment of patients included low-protein
diet that was adapted to the tolerance of the individual
combined with arginine and/or citrulline supplementa-
tion and sodium or glycerol phenylbutyrate and/or so-
dium benzoate administration, depending on the onset
and severity of the disease. Emergency treatment with
high-caloric intake providing glucose and lipids was per-
formed during catabolic states.
The data from the records analysis have been collected
in a secure electronic CRF (case report form), accessible
with an individual login and password (database
MySQL), developed by the Unité de Recherche Clinique
(URC) of Hôpital Robert Debré, AP-HP. This database
has been reported to the French computer watchdog au-
thorities (Comité Consultatif pour le Traitement de l’In-
formation en matière de Recherche pour la Santé,
CCTIRS, and Commission Nationale Informatique et
Liberté, CNIL). Records analysis and data monitoring
based on medical charts were conducted by a clinical re-
search associate who visited each centre over a one-year
period.
For each episode, the following information was col-
lected: triggering factors and initial and final biological
values, especially the ammonemia time course during
hospitalization. Other biological parameters included liver
enzymes, clotting factors, blood pH, blood bicarbonates,
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serum bilirubin. Concomitant treatments were recorded.
Adverse events (AEs) and deaths during hospitalization
were also reported.
Statistical analysis
Statistical analyses were performed using the R statistical
software (http://cran.r-project.org/) in the Clinical Re-
search Unit of Hôpital Necker, AP-HP. The data are pro-
vided for individuals and are essentially descriptive.
Where relevant for the description of the cohort, quanti-
tative data are expressed as the mean (± SD) or median




Sixty-one patients who were hospitalized at the 6 Refer-
ence centres in France and required i.v. sodium benzoate
were included in the study between November 2011 and
August 2012 : 26/61(42.6 %) from Necker-AP-HP Paris,
16/61 (26.2 %) from HCL Lyon, 6/61 (9.8 %) from Rob-
ert Debré-AP-HP Paris, 6/61 (9.8 %) from AP-HM
Marseille, 4/61 (6.6 %) from Lille, and 3/61 (4.9 %) from
Nancy.
A total of 95 episodes were identified for these 61 pa-
tients: 38/95 (40.0 %) from Necker-AP-HP Paris, 28/95
(29.5 %) from HCL Lyon, 11/95 (11.6 %) from Robert
Debré-AP-HP Paris, 10/95 (10.5 %) from AP-HM
Marseille, 4/95 (4.2 %) from Lille, and 4/95 from Nancy
(4.2 %).
The number of episodes per patient was 1 (n = 40:
68.6 %, mostly during the neonatal period), 2 (n =
14:23.0 %), and 3 (n = 4:6.6 %). Three patients underwent
4, 5 and 6 episodes of i.v. sodium benzoate treatment,
respectively. Of these patients, two presented with
OTCD and died, while the other one is still living with
ASSD.
The patients’ ages ranged from 0 to 35 years, with a
median age of 3.0 years. Over one-third of the patients
(42.1 %) were between 2 and 11 years old (Table 1).
The sex ratio of the patients in this study was 1:1
(50.8 % were female), although there was a slightly
higher number of episodes in the male patients (54 epi-
sodes versus 41 in female patients).
Thirty-nine (53.4 %) of the episodes were initial epi-
sodes of neonatal coma.
Enzyme deficiencies
OTCD was the most common enzyme deficiency
(32.8 %, 20/61 patients – 10 males, 10 females), followed
by ASSD (Table 2). Two patients had a suspicion of
OTCD and one patient had a triple H syndrome. All of
the patients except 2 (suspected of OTCD) had diagnos-
tic confirmation at the molecular level.
Indication for i.v. sodium benzoate administration
The most frequent cause of decompensation reported in
this study was infection (either benign or serious), with
20/36 episodes (55.5 %). The other causes were general
anaesthesia (11/36, 30.6 %), excessive consumption of
proteins (3/36, 8.3 %) and fasting (2/36, 5.6 %). Clear no-
tification of the reason for the administration of i.v. so-
dium benzoate was not retrospectively found for the
majority of the episodes (59/95 episodes, 62.1 %).
Neurological status
The patients’ neurological state and clinical symptoms
were recorded in the 24 h prior to the first infusion of so-
dium benzoate for each episode. Patients were in a coma
for 28.1 % of episodes (25/89 recorded episodes) and had
seizures for 18.6 % of episodes (16/86 recorded episodes).
Vomiting was present for 40.0 % of episodes, fever for
13.7 % and diarrhoea for 9.5 % of episodes (N= 95
episodes).
Doses of i.v. sodium benzoate administered
For 54 of the 95 episodes (56.8 %), the patients received
their first dose of i.v. sodium benzoate in the intensive
care unit, whilst for the other 41 episodes (43.2 %), the
first dose of i.v. sodium benzoate was administered in
other hospital departments.
A loading dose of i.v. sodium benzoate was given to
patients for 41 episodes (N = 95 episodes, 43.2 %) using
a peripheral line infusion. Precise dosage was missing for
Table 1 Number of episodes by age category
Age category Patients
N = 61 (%)
0–27 days 25 (26.3 %)
1-23 months 14 (14.7 %)
2–11 years 40 (42.1 %)
12–17 years 10 (10.5 %)
≥18 years 6 (6.3 %)
Table 2 Causes of UCD-related hyperammonemia
Causes Patients
N = 61 (%)
Episodes
N = 95 (%)
OTCD 20 (32.8 %) 35 (36.8 %)
ASSD 18 (29.5 %) 30 (31.6 %)
CPSD 15 (24.6 %) 18 (18.9 %)
ASLD 3 (4.9 %) 4 (4.2 %)
ARGD 1 (1.6 %) 2 (2.1 %)
NAGSD 1 (1.6 %) 2 (2.1 %)
Others 3 (4.9 %)* 4 (4.2 %)
*Suspected OTCD without a molecular basis N = 2, HHH syndrome N = 1
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6 of the episodes, but for the remaining 35 episodes, the
median loading dose was 250.0 mg/kg [14–425].
Maintenance doses were given by peripheral i.v. infu-
sion in most cases; a central i.v. line was used for only
one episode. The maximum dose administered during
the first period of treatment was missing for 21 of the
episodes, but for the remaining 74 episodes, the median
maximum dose was 246.1 mg/kg/day [25.7 –990.1].
The total treatment duration per episode was a median
of 2 days [0.1 –13].
The total duration of hospitalization in the intensive
care unit per episode (patients were admitted to the in-
tensive care unit for 54 episodes) was a median of 4 days
[0 –17], while the total duration of hospitalization per
episode was a median of 10 days [0 –70].
Efficacy
From a clinical point of view, the majority of the pa-
tients (69 %) had only one episode of hyperammoniemia;
the median age of these patients was 3 years [0 –35
years]. The first dose of i.v. sodium benzoate was admin-
istered to patients upon admission in the intensive care
unit of the hospital for 57 % of episodes and in other
hospital departments for 43 % of episodes.
Eight patients died during hospitalization. The causes
of death were the severe neonatal coma that revealed
the disease (3 OTCD, 2 CPSD, 1 ASSD), decompensa-
tion during surgery (portal vein recanalization) at age
3.6 years (OTCD), and complications in the immediate
course of liver transplantation at age 3.6 years (OTCD).
In terms of biological parameters the efficacy of i.v. so-
dium benzoate associated with emergency regimen was
assessed by the decrease in ammonemia below the limit
of 100 μmol/L by the end of i.v. sodium benzoate
treatment.
The ammonia results at the end of i.v. treatment were
missing for 18/95 episodes of this cohort; however after
these episodes, the corresponding patients were success-
fully discharged from hospital, implying that their
ammonia levels had returned to normal (or at least to
non-toxic) levels.
Of the 77/95 documented episodes, the median am-
monia level before i.v. sodium benzoate treatment was
245.5 μmol/L [20.0; 2274.0]. This median ammonemia
level decreased to 40.0 μmol/L [13.0; 181.0] by the end
of benzoate treatment. When we restricted the episodes
to those with ammonemia level before treatment >
100 μmol/L (69 episodes), the median ammonemia level
before i.v. sodium benzoate treatment was 291 μmol/L
[101 –2274]. This median ammonemia level decreased
to 41 μmol/L [13 –181] by the end of benzoate treat-
ment. The median degree of ammonemia at discharge
from hospital was 41 μmol/L [28.8; 48.0]. More pre-
cisely, the treatment was very successful (ammonemia ≤
100 μmol/L) for 64/69 of the episodes recorded for the
53 surviving patients/61 (92.8 %).
Ammonemia was still > 100 μmol/L at the end of i.v.
treatment for 5 episodes; however, these 5 patients were
successfully discharged from hospital, 4 with ammone-
mia ≤ 100 μmol/L at discharge (the results were missing
for one episode). These 5 patients received another
treatment for hyperammonemia at the end of their i.v.
sodium benzoate treatment (neonatal comas treated with
the combination of sodium phenylacetate and sodium
benzoate + haemofiltration or the combination of so-
dium phenylacetate and sodium benzoate alone).
Other treatments
Patients were treated with the combination of sodium
phenylacetate and sodium benzoate during 10 of the epi-
sodes (N= 94 episodes, one observation missing;
Table 3); for 6 of these episodes, the drug was given at
the end of the treatment with i.v. sodium benzoate.
Fifteen patients were treated with haemofiltration dur-
ing 16 episodes; for 6 of these episodes, haemofiltration
was provided at the end of treatment with i.v. sodium
benzoate.
Patients were treated with antibiotics during 43 of the
episodes (45.7 %, N = 94 episodes, one observation
missing).
At the end of treatment with i.v. sodium benzoate, the
most common treatment was the oral form of sodium
benzoate (sodium benzoate p.o., 78.3 %, 65/83 recorded
episodes). For 2/83 recorded episodes (2.4 %), no further
treatment was administered.
Safety
In this study, eighteen complications were related to the
infusion (extravasation of the venous catheter, local
Table 3 Other NH3 treatments provided at the end of treatment
with i.v. sodium benzoate (Emergency regimen was performed in
all cases)
Treatments Episodes
N = 95 (%)
Missing 12 (12.6 %)
Sodium benzoate p.o. 65 (78.3 %)a
Sodium benzoate p.o. + Phenylbutyrate p.o. 3 (3.6 %)a
Combination Sodium phenylacetate + Sodium
benzoate (central i.v. infusion)
3 (3.6 %)a
Combination Sodium phenylacetate + Sodium
benzoate (central i.v. infusion) + Haemofiltration
3 (3.6 %)a
Haemofiltration 2 (2.4 %)a
Haemofiltration + Phenylbutyrate p.o. 1 (1.2 %)a
Phenylbutyrate p.o. 1 (1.2 %)a
aCalculated as a percentage of the non-missing data
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oedema, local erythema, haematoma, local inflammation,
and local abscess).
Because of metabolic decompensation, neurological
signs were described in 19 episodes; liver symptoms
were noted in 22 episodes (10 liver failures and 12 cases
of liver cytolysis without liver failure). Also noted were 4
episodes of disseminated intravascular coagulation, 3
kidney failure episodes, one case of sepsis of the internal
jugular vein catheter with septic shock, one case of left
ventricular dysfunction, and one cardiorespiratory arrest
lasting 4 min.
Discussion
Sodium benzoate is an established and accepted adjunct-
ive therapy for UCDs, as mentioned in the European
guidelines [10], and for all causes of hyperammoniemia.
Clinicians have used i.v.sodium benzoate routinely from
the past 25 years to treat hyperammonemia in situations
of acute decompensation (hyperammonemia) and during
fasting, such as in cases of surgery or vomiting. Its effi-
cacy and safety have been well known for years by meta-
bolic physicians. Moreover, as previously reported (22),
the most frequent cause of metabolic decompensation in
our study was a catabolism episode, such as an infection.
This underlines assertions that the availability of intra-
venous sodium benzoate is crucial for the management
of UCD patients [23].
However, i.v. sodium benzoate has no marketing au-
thorisation, and very little information on the use of this
drug has been published. This retrospective study was
established in 2011–2012 to consolidate the French phy-
sicians’ previous clinical experiences in the treatment of
hyperammonemia in recent years. Data from 61 patients
and 95 episodes of hyperammonemia were analysed dur-
ing this study. These data showed that i.v. sodium
benzoate decreased ammonia levels to ≤ 100 μmol/L by
the end of treatment in most cases of late decompensa-
tion and that normal levels of NH3 were maintained in
other situations where this treatment was prescribed to
prevent decompensation. Also, this treatment is used for
the prevention of decompensations and for the treat-
ment of overt decompensations. Before treatment, the
median ammonemia level was 246 μmol/L whatever the
situations (overt decompensation or prevention of de-
compensation) (range: 20–2274 μmol/L, N = 82 epi-
sodes); it decreased to 40 μmol/L (range: 13–181 μmol/
L, N= 77 episodes) among the patients who were still
alive at the end of treatment with i.v. sodium benzoate.
Deaths were caused by the underlying metabolic disease
and occurred during the neonatal coma in 6 cases and
during surgery/liver transplantation in 2 patients. Our
study also confirmed that OTCD and ASSD are the
most frequent UCDs (33 % and 30 %, respectively), while
OTCD and CPSD are the most severe (representing all
deaths in our study). It is well established that deaths
occur mainly in severe neonatal coma, usually caused by
OTCD and CPSD.
Because the first dose of i.v. sodium benzoate may be
administered to patients both in the intensive care unit
of the hospital than in other hospital departments, it is
important for local hospitals to have i.v. sodium benzo-
ate readily available before transferring a patient to a ref-
erence centre. Importantly, our work described the use
of i.v. sodium benzoate in patients hospitalized in the
French reference centers only. It is not representative of
all episodes of hospitalizations and decompensations of
the patients who firstly go to their nearby hospital, with
telephone advices and emergency certificates from their
reference center. Moreover initial comas are not
managed only in reference centers as to date a lot of
hospitals perform haemodialysis and acute medical treat-
ments. All these considerations reinforce the necessity
to have i.v. medications readily available in the whole na-
tional territory. The use of nitrogen scavengers is crucial,
but of course associated with an intensive care manage-
ment including rehydration, induction of anabolism with
adequate amounts of calories, administration of i.v. ar-
ginine, carglumic acid for NAGS, CAVA and sometimes
CPS1 deficiencies.
In our cohort, eighteen side effects were related to the
infusion (extravasation of the venous catheter, local
oedema, inflammation or abscess, haematoma). They were
probably under-estimated in this retrospective study, but
importantly no severe side effects were attributed specific-
ally to i.v. sodium benzoate. Serious complications like
comas, death and liver failure have been attributed to the
underlying UCD and its decompensations.
A loading dose of i.v. sodium benzoate was given for
43 % of episodes, and the dose was variable. The fact
that there were no guidelines available for most of the
study period probably contributed to the lack of
consistency in the administration and reporting of load-
ing doses. Maintenance doses were given via peripheral
i.v. infusion in most cases; central i.v. infusion was used
for only one episode. The median maximum dose was
246.1 mg/kg/day, in accordance with the guidelines [10].
The total duration of i.v. sodium benzoate treatment
per episode was a median of 2 days [0.1 –13], patients
stayed in the intensive care unit for a median of 4 days,
and the total length of stay in hospital was a median of
10 days. This point is important to note: not only the
peak of plasma ammonium level, but also the duration
of hyperammoniemia until normalization, have an im-
pact on the outcome. More precisely, ammonemia was
still > 100 μmol/L at the end of i.v. treatment for only 5
episodes. However, the 5 patients were successfully dis-
charged from hospital (4 with ammonemia ≤ 100 μmol/L
at discharge, the results were missing for one episode).
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During 10 episodes, patients were treated with the
combination of sodium phenylacetate and sodium
benzoate (administered via central i.v. infusion) in asso-
ciation with i.v. sodium benzoate. This underlines the
interest in i.v. sodium benzoate, which only requires per-
ipheral vein access. Haemofiltration was required for 16
episodes, mostly in cases of neonatal coma for which i.v.
sodium benzoate was not sufficient.
In our study, i.v. benzoate was switched to the oral
form of sodium benzoate (sodium benzoate p.o., 78.3 %,
65/83 recorded episodes).
Whilst data were being collected for this French study,
Häberle et al. published guidelines with the aim of har-
monising the diagnosis and management of UCD in Eur-
ope [10]. These guidelines pool the results of and
experience with all UCD treatments from several Euro-
pean countries, with most of the evidence based on ex-
pert opinion or case studies because of a lack of formal
clinical trial data in Europe. The guidelines state that the
ammonia scavengers sodium benzoate and sodium phe-
nylacetate (one of the 2 active ingredients in the com-
bination of sodium phenylacetate and sodium benzoate,
along with sodium benzoate) are among the main treat-
ments for acute hyperammonemia. The dose of i.v. so-
dium benzoate quoted in the guidelines is the same as
that suggested in the product information sheet pro-
vided by AGEPS, AP-HP, which summarizes the doses of
sodium benzoate AP-HP 1 g/10 mL to be used in clin-
ical practice in France.
The experiences of the French clinicians indicated that
i.v. sodium benzoate has advantages over the other treat-
ments mentioned above. First of all, it can be adminis-
tered during a coma or in cases of gastroenteritis,
whereas the p.o. drugs containing sodium or glycerol
phenylbutyrate cannot be used or are not well absorbed;
and secondly, it is administered via a peripheral venous
catheter, which is thought to be less risky [16, 20] and
more practical than administration via a central venous
catheter, as is the required for the combination of so-
dium phenylacetate and sodium benzoate. Another ad-
vantage concerns the availability of the products: i.v.
sodium benzoate is available in France with a hospital
preparation status, whereas the combination of sodium
phenylacetate and sodium benzoate has to be imported
on a named-patient basis from the USA (it has tempor-
ary use agreement —ATU - status in France). These ad-
vantages make i.v. sodium benzoate an essential tool in
the treatment of hyperammoniemia, and all hospitals
should own this treatment, particularly to treat the pa-
tient during the transfer to a specialized hospital. Im-
portantly, secondary care centres and local hospitals
may need to treat hyperammonemic decompensations
related to UCD, as reference centres may have difficulty
managing all UCD patients.
Conclusion
The 10-year retrospective study from 2000 until 2010 in
the 6 French reference centrers for metabolic diseases
shows that i.v. sodium benzoate treatment is effective
for the treatment and/or the prevention of hyperammo-
nemia in UCD. This study also confirms the safety of
this treatment. I.v. sodium benzoate is the only periph-
eral treatment recommended and used in France in
acute episodes of UCD, associated with an emergency
regimen. Consequently, this precious i.v. treatment
should be readily available in emergency in all hospitals.
Acknowledgements
This study was sponsored by Etablissement Pharmaceutique des Hôpitaux de
Paris, AP-HP. We also thank Dr Eric Bauchart, Dr Hélène Ogier de Baulny and
Pr Jean-Hugues Trouvin for their contributions to the study. Medical writing
assistance was provided by Kirsten Dumaz from Keyrus Biopharma.
Funding
This research has not received any funding.
Availability of data materials
The data from the records analysis have been collected in a secure
electronic CRF (case report form), accessible with an individual login and
password (database MySQL), developed by the Unité de Recherche Clinique
(URC) of Hôpital Robert Debré (AP-HP, Paris). The data management has
been realized under the responsability of Pr ALBERTI, URC Robert Debré.
Statistical analyses were performed using the R statistical software (http://
cran.r-project.org/) in the Clinical Research Unit of Hôpital Necker, AP-HP
under the responsability of Pr Paul LANDAIS.
Authors’ contributions
MCH, DD, JBA, AC, AB, VV, BC, FF, NG, PdL, were involved in data collection.
CE was involved in the statistical analysis. All authors received the manuscript.
All authors read and approved the final draft and agreed to be accountable for
the accuracy and integrity of the work.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
This manuscript does not contain any individual persons data.
Ethics Approval and Consent to Participate
This research is a retrospective observational study.
The six reference centres enrolled in this retrospective study were asked to
retrieve the medical records of all patients with UCD who had been
hospitalized between January 2000 and December 2010.
A database has been created and reported to the French computer
watchdog authorities (Comité Consultatif pour le Traitement de l’Information
en matière de Recherche pour la Santé, CCTIRS, and Commission Nationale
Informatique et Liberté, CNIL).
Records analysis and data monitoring based on medical charts were
conducted by a clinical research associate who visited each centre over a
one-year period.
Author details
1Etablissement Pharmaceutique des Hôpitaux de Paris, AGEPS, 7 rue du Fer à
Moulin, Paris 75005, France. 2Centre de Référence des Maladies Héréditaires
du Métabolisme, Hôpital Robert-Debré, AP-HP, Paris, France. 3Reference
Centre for Inherited Metabolic Disorders, Hôpital Femme Mère-Enfant, Lyon,
France. 4Centre de Référence des Maladies Héréditaires du Métabolisme,
CHU Timone Enfants, Marseille, France. 5Centre de Référence des Maladies
Héréditaires du Métabolisme, Hôpital Jeanne-de-Flandre, CHRU Lille, Lille,
France. 6Reference Centre for Inherited Metabolic Disorders (MaMEA), Hôpital
Necker-Enfants Malades, Institut Imagine, Université Paris Descartes, 149 rue
de Sèvres, 75743, Paris Cedex 15, France. 7Centre de Référence des Maladies
Husson et al. Orphanet Journal of Rare Diseases  (2016) 11:127 Page 7 of 8
Héréditaires du Métabolisme, CHU de Nancy, Hôpital Brabois Enfants,
Vandoeuvre-les-Nancy, France. 8URC/CIC Paris Centre, Hôpital Universitaire
Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France.
Received: 1 July 2016 Accepted: 6 September 2016
References
1. Msall M, Monahan PS, Chapanis N, Batshaw ML. Cognitive development in
children with inborn errors of urea synthesis. Acta Paediatr Jpn. 1988;30:
435–41.
2. Batshaw ML, Tuchman M, Summar M, Seminara J. Members of the Urea
Cycle Disorders Consortium. A longitudinal study of urea cycle disorders.
Mol Genet Metab. 2014;113(1–2):127–30.
3. Summar M, Kölker S, Freedenberg D, Le Mons C, Häberle J, Lee HS, Kirmse
B. The Eutopean Registry and Network for Intoxication Type Metabolic
Diseases (E-IMD), and the members of the Urea Cycle Disorders Consortium
(UCDC). The incidence of urea cycle disorders. Mol Genet Metab. 2013;110:
179–80.
4. Summar M, Tuchman M. Proceedings of a consensus conference for the
management of patients with urea cycle disorders. J Pediatr. 2001;138:S6–10.
5. Kamoun PP, Rabier D. Valproate-induced inhibition of urea synthesis. Lancet.
1987;1:48.
6. Burgard P, Kölker S, Haege G, Lindner M, Hoffmann GF. Neonatal mortality
and outcome at the end of the first year of life in early onset urea cycle
disorders–review and meta-analysis of observational studies published over
more than 35 years. J Inherit Metab Dis. 2016;39(2):219–29.
7. Kölker S. The phenotypic spectrum of organic acidurias and urea cycle
disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38(6):
1041–57.
8. Posset R. Age at disease onset and peak ammonium level rather than
interventional variables predict the neurological outcome in urea cycle
disorders. J Inherit Metab Dis. 2016;39(5):661–72.
9. Waisbren SE. Improving long term outcomes in urea cycle disorders-report
from the Urea Cycle Disorders Consortium. J Inherit Metab Dis. 2016;39(4):
573–84.
10. Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall
D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Lindner
M, Rubio V, Dionisi-Vici C. Suggested guidelines for the diagnosis and
management of urea cycle disorders. Orphanet J Rare Dis. 2012;7:32.
11. Feillet F, Leonard JV. The long-term treatment of patients with urea cycle
disorders (UCDs) includes diet treatment and use. J Inherit Metab Dis. 1998;
21 Suppl 1:101–11.
12. Saudubray JM, Nuoffer JM, de Lonlay P, Castelnau P, Touati G. Les maladies
héréditaires du métabolisme à l’age adulte. Rev Med Interne. 1998;19 Suppl
3:366–75.
13. Walker V. Ammonia toxicity and its prevention in inherited defects of the
urea cycle. Diabetes Obes Metab. 2009;11(9):823–35.
14. Leonard JV, Ward Platt MP, Morris AA. Hypothesis: proposals for the
management of a neonate at risk of hyperammonaemia due to a urea cycle
disorder. Eur J Pediatr. 2008;167(3):305–9. Epub 2007 Apr 14.
15. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival
after treatment with phenylacetate and benzoate for urea cycle disorders.
N Engl J Med. 2007;356:2282–92.
16. Msall M, Batshaw ML, Suss R, Brusilow SW, Mellits ED. Neurologic outcome
in children with inborn errors of urea synthesis. Outcome of urea-cycle
enzymopathies. N Engl J Med. 1984;310(23):1500–5.
17. Bonnemains C, Feillet F. Diagnosis and management of hyperammonemia.
Arch Pediatr. 2009;16:634–6.
18. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology,
and therapy. Adv Pediatr. 1996;43:127–70.
19. Arnoux JB, Valayannopoulos V, Dupic L, Postaire M, Rabier D, de Lonlay P.
Management of hyperammoniemic coma in neonates with UCD using an i.
v. equimolar solution of sodium benzoate and sodium phenylacetate
(AMMONUL®). Mol Genet Metab. 2009;98:119–48.
20. O’Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, Maki DG,
Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A,
Weinstein RA. Guidelines for the prevention of intravascular catheter-related
infections. Centers for Disease Control and Prevention. MMWR Recomm
Rep. 2002;51(RR-10):1–29.
21. Braun MC, Welch TR. Continuous venovenous hemodiafiltration in the
treatment of acute hyperammonemia. Am J Nephrol. 1998;18:531–3.
22. Schmidt J, Schroth M, Irouschek A, Birkholz T, Kurzai M, Kröber S, Meisner M,
Albrecht S. Patients with ornithine transcarbamylase deficiency.
Anaesthesiological and intensive care management. Anaesthesist. 2005;
54(12):1201–8.
23. Rüegger CM, Lindner M, Ballhausen D, Baumgartner MR, Beblo S, Das A,
Gautschi M, Glahn EM, Grünert SC, Hennermann J, Hochuli M, Huemer M,
Karall D, Kölker S, Lachmann RH, Lotz-Havla A, Möslinger D, Nuoffer JM,
Plecko B, Rutsch F, Santer R, Spiekerkoetter U, Staufner C, Stricker T, Wijburg
FA, Williams M, Burgard P, Häberle J. Cross-sectional observational study of
208 patients with non-classical urea cycle disorders. J Inherit Metab Dis.
2014;37(1):21–30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Husson et al. Orphanet Journal of Rare Diseases  (2016) 11:127 Page 8 of 8
